Drug Profile
ONO 4474
Alternative Names: ONO-4474Latest Information Update: 09 Mar 2021
Price :
$50
*
At a glance
- Originator Ono Pharmaceutical
- Class Analgesics; Anti-inflammatories; Antirheumatics
- Mechanism of Action Tropomyosin-related kinase antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Pain
Most Recent Events
- 09 Mar 2021 No development reported - Phase-I/II for Pain (In the elderly, In adults) in Japan (PO) (Ono Pharmaceutical pipeline, March 2021)
- 19 Oct 2018 Final safety and efficacy data from a phase I/II trial in Pain presented at the 82nd American College of Rheumatology and the 52nd Association of Rheumatology Health Professionals Annual Scientific Meeting (ACR/ARHP-2018)
- 09 Jan 2018 Ono Pharmaceutical terminates the MOTION phase II trial in Pain (In the elderly, In adults) in Denmark, United Kingdom, Hungary, Spain, Poland due to business reasons (PO) (NCT02997696)